Surrogate endpoint
Top View
- Time to Review the Role of Surrogate Endpoints in Health Policy: State of the Art and the Way Forward
- Of Adaptive Design Clinical Trials for Drugs and Biologics Guidance
- Considerations for the Use of Biomarkers in the Study of Rare Diseases
- Endpoints in Vaccine Trials
- Surrogate Endpoints in Oncology Clinical Trials: Are We There Yet? from a Practical Perspective
- Review of Meta-Analyses Evaluating Surrogate Endpoints for Overall Survival in Oncology
- Assay Validation and Reproducibility Considerations for Biomarkers Used in Drug Development
- FDA Briefing Document Developing Antibacterial Therapies Targeting A
- Endpoint Surrogacy in Oncology Phase 3 Randomised Controlled Trials
- Outcomes, Surrogates, Composite Endpoints (Day)
- Usage of Surrogate Endpoints in the Design and Analysis of Clinical Trials
- Predictive Probability of Success Using Surrogate Endpoints
- Innovative Clinical Study Design for Gene and Cell Therapies Jake Elkins, MD Head, Clinical Sciences Sarepta Therapeutics Problem Statement
- A Randomised Controlled Trial Is Not a Pilot Trial Simply Because It Uses a Surrogate Endpoint
- Developing Antiretroviral Drugs for Treatment Guidance for Industry
- Mechanistic Evidence in Evidence-Based Medicine: a Conceptual Framework
- Validation of Surrogate Endpoints for Clinical Trials
- Evaluating a Surrogate Endpoint at Three Levels, with Application to Vaccine Development